Current published literature regarding Afirma® and Thyroseq® V2 validation studies are summarized in Tables 2 and 3. The data were summarized from the results of a PubMed search for English language studies that reported diagnostic accuracy in observational clinical settings published for GEC and Thyroseq® V2 up to November 30, 2017. References from the retrieved articles were also searched for additional studies. Inclusion criteria included reporting molecular marker diagnostic accuracy or enough information to calculate sensitivity, specificity, NPV, and PPV among Bethesda Type III or IV lesions. All calculations were made using the available published information. To adhere to current clinical guidelines, non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and malignant pathologies were categorized as malignant or “requiring resection.” Of the published literature, only two studies included pediatric patients in their cohort (31, 32).